Efficacy and safety of ninjinyoeito, Japanese Kampo medicine, on peripheral neuropathy and anemia induced by oxaliplatin

Efficacy and safety of ninjinyoeito, Japanese Kampo medicine, on peripheral neuropathy and anemia induced by oxaliplatin - HOPE-2

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000014207

Enrollment

Registered

2014-06-10

Start date

2014-01-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal cancer

Interventions

FOLFOX or XELOX with ninjinyoeito FOLFOX or XELOX without ninjinyoeito

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Histopathologically-proven colorectal cancer 2. Pathological stage is stage IIIa or IIIb 3. Curative A operation was performed 4. No prior treatments such as chemotherapy, immunotherapy, or radiation therapy for pain control

Exclusion criteria

Exclusion criteria: 1. Prior blood transfusion or G-CSF administration 2. Severe drug hypersensitivity 3. Peripheral neuropathy due to diabetes mellitus etc. 4. diabetes mellitus requiring insulin therapy

Design outcomes

Primary

Measure	Time frame
peripheral neuropathy	—

Secondary

Measure	Time frame
hemoglobin concentration neutrophi count platelet count	—

Countries

Japan

Contacts

Public ContactKazuho HIsamura

Kanazawa Medical University Department of Medical Oncology

hisamura@kanazawa-med.ac.jp076-286-2211

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026